Home > Rheumatology > ACR 2021 > ACR 2021 Highlights Podcast

ACR 2021 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
ACR 2021

In this episode (18.28 min), Medicom’s correspondent covers 6 presentations from American College of Rheumatology Convergence 2021 (ACR Convergence 2021), held virtually 3–9 November 2021.

The topics discussed are:

  1. A new xanthine oxidase inhibitor for gout is on the horizon
    Tigulixostat showed clear benefit in patients with gout and hyperuricemia for its serum urate-lowering capacity. The drug was overall well tolerated and without particular safety signals. These results support dose finding and continued development of tigulixostat.
  2. Therapy of PsA: no benefit of adding methotrexate to IL-12/IL-23 inhibitor
    Patients with active psoriatic arthritis are better off with monotherapy with ustekinumab compared with the combination of methotrexate and ustekinumab. The combination causes more side effects and does not enhance efficacy or quality of life in these patients.
  3. Antifibrotic agent slows progression in RA-associated interstitial lung disease
    Patients with rheumatoid arthritis and associated interstitial lung disease could be safely treated with pirfenidone, the TRAIL1 study showed. In participants receiving the antifibrotic, lung function decline was slowed down, particularly in those with a baseline usual interstitial pneumonia pattern.
  4. Rituximab for rheumatoid arthritis: ultra-low dosing works
    Ultra-low dosing of rituximab seems a viable option also in long-term treatment for rheumatoid arthritis (RA). The efficacy of 500 mg and 200 mg regimens were non-inferior to 1000 mg when following patients for up to 4 years.
  5. Laboratory and clinical data predicts the development of multisystem inflammatory syndrome in children
    A retrospective chart review analysis in the first 24 hours after hospital admission revealed 4 predictors that discriminate between children with multisystem inflammatory syndrome and other syndromes: hypotension, abdominal pain, rash, and serum sodium concentration.
  6. Iberdomide shows promise for lupus treatment
    Iberdomide, a fourth generation high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors which partially determine the genetic risk for systemic lupus erythematosus, demonstrated sustained efficacy in the second part of its phase 2 assessment. The agent leads to sustained and meaningful improvements in lupus disease activity and was overall well tolerated.

Enjoy listening!

Copyright ©2021 Medicom Medical Publishers

Posted on